Cargando…
Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study
We assessed the association of sex hormone levels with breast cancer risk in a case–control study nested within the cohort of 7054 New York University (NYU) Women's Health Study participants who were postmenopausal at entry. The study includes 297 cases diagnosed between 6 months and 12.7 years...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395327/ https://www.ncbi.nlm.nih.gov/pubmed/14710223 http://dx.doi.org/10.1038/sj.bjc.6601517 |
_version_ | 1782155481304793088 |
---|---|
author | Zeleniuch-Jacquotte, A Shore, R E Koenig, K L Akhmedkhanov, A Afanasyeva, Y Kato, I Kim, M Y Rinaldi, S Kaaks, R Toniolo, P |
author_facet | Zeleniuch-Jacquotte, A Shore, R E Koenig, K L Akhmedkhanov, A Afanasyeva, Y Kato, I Kim, M Y Rinaldi, S Kaaks, R Toniolo, P |
author_sort | Zeleniuch-Jacquotte, A |
collection | PubMed |
description | We assessed the association of sex hormone levels with breast cancer risk in a case–control study nested within the cohort of 7054 New York University (NYU) Women's Health Study participants who were postmenopausal at entry. The study includes 297 cases diagnosed between 6 months and 12.7 years after enrollment and 563 controls. Multivariate odds ratios (ORs) (95% confidence interval (CI)) for breast cancer for the highest quintile of each hormone and sex-hormone binding globulin (SHBG) relative to the lowest were as follows: 2.49 (1.47–4.21), P(trend)=0.003 for oestradiol; 3.24 (1.87–5.58), P(trend)<0.001 for oestrone; 2.37 (1.39–4.04), P(trend)=0.002 for testosterone; 2.07 (1.28–3.33), P(trend)<0.001 for androstenedione; 1.74 (1.05–2.89), P(trend)<0.001 for dehydroepiandrosterone sulphate (DHEAS); and 0.51 (0.31–0.82), P(trend)<0.001 for SHBG. Analyses limited to the 191 cases who had donated blood five to 12.7 years prior to diagnosis showed results in the same direction as overall analyses, although the tests for trend did not reach statistical significance for DHEAS and SHBG. The rates of change per year in hormone and SHBG levels, calculated for 95 cases and their matched controls who had given a second blood donation within 5 years of diagnosis, were of small magnitude and overall not different in cases and controls. The association of androgens with risk did not persist after adjustment for oestrone (1.08, 95% CI=0.92–1.26 for testosterone; 1.15, 95% CI=0.95–1.39 for androstenedione and 1.06, 95% CI=0.90–1.26 for DHEAS), the oestrogen most strongly associated with risk in our study. Our results support the hypothesis that the associations of circulating oestrogens with breast cancer risk are more likely due to an effect of circulating hormones on the development of cancer than to elevations induced by the tumour. They also suggest that the contribution of androgens to risk is largely through their role as substrates for oestrogen production. |
format | Text |
id | pubmed-2395327 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23953272009-09-10 Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study Zeleniuch-Jacquotte, A Shore, R E Koenig, K L Akhmedkhanov, A Afanasyeva, Y Kato, I Kim, M Y Rinaldi, S Kaaks, R Toniolo, P Br J Cancer Epidemiology We assessed the association of sex hormone levels with breast cancer risk in a case–control study nested within the cohort of 7054 New York University (NYU) Women's Health Study participants who were postmenopausal at entry. The study includes 297 cases diagnosed between 6 months and 12.7 years after enrollment and 563 controls. Multivariate odds ratios (ORs) (95% confidence interval (CI)) for breast cancer for the highest quintile of each hormone and sex-hormone binding globulin (SHBG) relative to the lowest were as follows: 2.49 (1.47–4.21), P(trend)=0.003 for oestradiol; 3.24 (1.87–5.58), P(trend)<0.001 for oestrone; 2.37 (1.39–4.04), P(trend)=0.002 for testosterone; 2.07 (1.28–3.33), P(trend)<0.001 for androstenedione; 1.74 (1.05–2.89), P(trend)<0.001 for dehydroepiandrosterone sulphate (DHEAS); and 0.51 (0.31–0.82), P(trend)<0.001 for SHBG. Analyses limited to the 191 cases who had donated blood five to 12.7 years prior to diagnosis showed results in the same direction as overall analyses, although the tests for trend did not reach statistical significance for DHEAS and SHBG. The rates of change per year in hormone and SHBG levels, calculated for 95 cases and their matched controls who had given a second blood donation within 5 years of diagnosis, were of small magnitude and overall not different in cases and controls. The association of androgens with risk did not persist after adjustment for oestrone (1.08, 95% CI=0.92–1.26 for testosterone; 1.15, 95% CI=0.95–1.39 for androstenedione and 1.06, 95% CI=0.90–1.26 for DHEAS), the oestrogen most strongly associated with risk in our study. Our results support the hypothesis that the associations of circulating oestrogens with breast cancer risk are more likely due to an effect of circulating hormones on the development of cancer than to elevations induced by the tumour. They also suggest that the contribution of androgens to risk is largely through their role as substrates for oestrogen production. Nature Publishing Group 2004-01-12 2004-01-06 /pmc/articles/PMC2395327/ /pubmed/14710223 http://dx.doi.org/10.1038/sj.bjc.6601517 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Epidemiology Zeleniuch-Jacquotte, A Shore, R E Koenig, K L Akhmedkhanov, A Afanasyeva, Y Kato, I Kim, M Y Rinaldi, S Kaaks, R Toniolo, P Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study |
title | Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study |
title_full | Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study |
title_fullStr | Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study |
title_full_unstemmed | Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study |
title_short | Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study |
title_sort | postmenopausal levels of oestrogen, androgen, and shbg and breast cancer: long-term results of a prospective study |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395327/ https://www.ncbi.nlm.nih.gov/pubmed/14710223 http://dx.doi.org/10.1038/sj.bjc.6601517 |
work_keys_str_mv | AT zeleniuchjacquottea postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy AT shorere postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy AT koenigkl postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy AT akhmedkhanova postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy AT afanasyevay postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy AT katoi postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy AT kimmy postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy AT rinaldis postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy AT kaaksr postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy AT toniolop postmenopausallevelsofoestrogenandrogenandshbgandbreastcancerlongtermresultsofaprospectivestudy |